Lorus completes private placement

Lorus Therapeutics (TSX:LOR) has closed a private placement of 1,581,667 common shares at a price of $1.05 each for gross proceeds of $1,660,750. Herbert Abramson, a director of Lorus, subscribed for 1,410,000 common shares, raising his stake to 6,437,811 shares, or a 41% interest. If he were to exercise his options and warrants, he would [...]

Lorus gets U.S. patent allowance for small molecule

Lorus Therapeutics (TSX:LOR) has received its first patent allowance in the U.S. for novel drug candidates from its small molecule program. The patent covers composition of matter of Lorus’ lead antimicrobial compound LOR-220 and related small molecules. It also provides Lorus with patent protection for antimicrobial compositions based on LOR-220 for inhibiting growth of a [...]

Lorus sets $5.5 million rights offering

Lorus Therapeutics (TSX:LOR) has filed with securities regulators in Canada for a rights offering that would give shareholders one right for each common share held as of Oct. 12, 2010. Each two rights will entitle holders to purchase one unit of Lorus at a price of $1.11 each. Each unit consists of one common share and [...]

Lorus antibacterial research in peer-reviewed journal

Research by Lorus Therapeutics (TSX:LOR; OTCBB:LRUSF) investigators describing synthesis and antibacterial activity of novel antimicrobial compounds from the company’s small molecule program has been published in the peer-reviewed journal Bioorganic & Medicinal Chemistry Letters. The research details activity of a series of new compounds against multi-drug resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA). The [...]

FDA clears Phase 1 study of Lorus drug

The FDA has approved Lorus Therapeutics’ (TSX:LOR) investigational new drug application for its anti-cancer drug candidate, LOR-253. The company said it now plans to proceed with a first-in-man Phase 1 dose escalation trial with LOR-253 in advanced or metastatic solid tumours at Memorial Sloan-Kettering Cancer Center in New York. The trial will study the safety [...]

Lorus presents Phase 2 data for LOR-2040

Lorus Therapeutics (TSX:LOR) has presented Phase 2 clinical trial data for its LOR-2040 drug in combination with high-dose cytarabine (HiDAC) in the treatment of acute myeloid leukemia at the European Hematology Association congress in Spain. In the 25-patient Phase 2 study, 28% achieved complete remission or CR with incomplete blood count recovery. Additionally, one patient [...]

Lorus files preliminary short-form prospectus

Lorus Therapeutics (TSX:LOR; OTCBB: LRUSF) has filed a preliminary short-form prospectus in Ontario, Alberta and British Columbia, and an amendment to the registration statement on Form F-1, initially filed in the U.S. in April, in connection with an offering of up to $17.5-million (U.S.) of units. Each unit will consist of one common share and one-half [...]

Publication reviews efficacy of Lorus’ interleukin 17E

Lorus Therapeutics (TSX:LOR) reports that the peer-reviewed journal, Cancer Immunology Immunotherapy, has published an article that outlines the anti-tumour activity of a novel cytokine interleukin 17E (IL-17E) and data of its mechanism of action. In the article, Lorus scientists demonstrated the anti-tumour effects of IL-17E in preclinical models, using it alone and in combination with [...]